Adherence to Quality-of-Care Indicators and Mortality Outcomes in Patients With MRSA Bacteremia
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.23220 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2025. Verfasst von I Russel Lee und 27 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Infectious Diseases, Singapore. Hauptthemen laut MEDLINE: Bacteremia, Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections, Anti-Bacterial Agents. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Importance Adherence to quality-of-care indictors (QCIs) is associated with better Staphylococcus aureus bacteremia (SAB) outcomes. It is unknown whether clinical trial participation adventitiously improves QCI adherence and clinical outcomes compared with nontrial routine care for SAB.
Objective
To evaluate whether health care practitioners of trial participants with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia have better QCI adherence compared with practitioners of contemporaneous nontrial patients with MRSA bacteremia and whether QCI adherence or trial participation is associated with lower mortality. Design, Setting, and Participants This ad hoc, post hoc analysis of the Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus (CAMERA2) Trial included 17 CAMERA2 hospital sites from 4 countries. The present study involved data collection mirroring the CAMERA2 case report forms from nontrial patients selected from sites’ CAMERA2 screening logs. The newly collected data were analyzed with existing data from trial participants. Both groups of patients were diagnosed with MRSA bacteremia between August 2015 and July 2018. Statistical analyses were performed from September 2024 to February 2025. Exposures Nontrial vs trial participation, including health care practitioner adherence to 7 evidence-based QCIs (individually and collectively) for SAB management. Main Outcome and Measures All-cause 90-day mortality; the association of the exposures with this outcome was assessed using Cox proportional hazards regressions. Multiple sensitivity analyses were performed, including propensity score matching and exclusion of early deaths.
Results
This study included 722 participants (467 nontrial [64.7%] and 255 trial [35.3%]; mean [SD] age, 63.2 [18.4] years; 482 [66.8%] male). Demographics were comparable in the 2 study groups. Nontrial patients had a higher range of Charlson Comorbidity Index (median, 2.0 [range, 0-16.0] vs 2.0 [range, 0-13.0]; P < .001) and Pitt bacteremia score (median, 1.0 [range, 1.0-12.0] vs 1.0 [range, 1.0-7.0]; P < .001) compared with trial participants. Ninety-day mortality was not significantly different in the nontrial and trial groups (106 of 457 [23.2%] vs 48 of 251 [19.1%]; P = .25). Health care practitioners of nontrial patients had a lower mean (SD) number of adherent QCIs compared with practitioners of trial participants (3.90 [1.38] vs 4.28 [1.17]; P = .003). While increasing number of adherent QCIs was associated with lower 90-day mortality (adjusted hazard ratio [AHR], 0.73; 95% CI, 0.59-0.91; P = .005), adherence to QCIs individually was not associated with lower mortality. Study group (nontrial vs trial) was not associated with mortality (AHR, 1.08; 95% CI, 0.73-1.61; P = .68). Conclusions and Relevance In this post hoc analysis of a randomized clinical trial, health care practitioners of trial participants had greater adherence to QCIs for MRSA bacteremia management compared with practitioners of nontrial patients. Trial participation was not associated with lower mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Centre for Infectious Diseases, Singapore.
- Communicable Diseases Agency, Singapore.
- Singapore Clinical Research Institute, Consortium for Clinical Research and Innovation, Singapore.
- Centre for Infectious Diseases and Microbiology, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.
- New South Wales Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia.
- Department of Infectious Diseases, Blacktown Hospital, Blacktown, New South Wales, Australia.
Zitieren
APA
Lee, I. R., Zhu, Y., Rai, N. J., O'Sullivan, M., Dotel, R., Robinson, J. O., Holmes, N. E., Tramontana, A. R., Sud, A., Davies, J., Van Wessel, C., Mckew, G. L., Gray, T. J., Runnegar, N., Schneider, K., Walls, G. B., Archuleta, S., Kalimuddin, S., Shi, L., …, & Combination Antibiotics for Methicillin-Resistant (CAMERA2) Study Group (2025). Adherence to Quality-of-Care Indicators and Mortality Outcomes in Patients With MRSA Bacteremia. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.23220
Vancouver
Lee IR, Zhu Y, Rai NJ, O'Sullivan M, Dotel R, Robinson JO, et al. Adherence to Quality-of-Care Indicators and Mortality Outcomes in Patients With MRSA Bacteremia. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.23220
BibTeX
@article{Lee2025,
author = {Lee, I Russel and Zhu, Yanan and Rai, Neela J and O'Sullivan, Matthew and Dotel, Ravindra and Robinson, J Owen and Holmes, Natasha E and Tramontana, Adrian R and Sud, Archana and Davies, Jane and Van Wessel, Cathrine and Mckew, Genevieve L and Gray, Timothy J and Runnegar, Naomi and Schneider, Kellie and Walls, Genevieve B and Archuleta, Sophia and Kalimuddin, Shirin and Shi, Luming and Dishon, Yael and Darawsha, Basel and Paul, Mical and Daitch, Vered and Yahav, Dafna and Tong, Steven Y C and Davis, Joshua S and Lye, David C and Combination Antibiotics for Methicillin-Resistant (CAMERA2) Study Group, Combination Antibiotics for Methicillin-Resistant (CAMERA2) Study Group},
title = {Adherence to Quality-of-Care Indicators and Mortality Outcomes in Patients With MRSA Bacteremia},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.23220}
}
EUVIMED